Large-cell neuroendocrine carcinoma (LCNEC) of the thymus is a rare aggressive neoplasm. Its precise prognosis has not yet been determined. The recently published European Society of Medical Oncology (ESMO) clinical practice guidelines for neuroendocrine bronchial and thymic tumors [1] defined LCNEC and small-cell carcinoma (SCC) of the thymus as high-grade thymic carcinoids with a 5-year survival rate of <10%. However, the prognostic value of present classification of thymic lesions has not been proven [2] .
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